"The U.S. Food and Drug Administration today expanded the approved use of Opdivo (nivolumab) to treat patients with advanced (metastatic) squamous non-small cell lung cancer (NSCLC) with progression on or after platinum-based chemotherapy.
ATGAM (lymphocyte immune globulin) Sterile Solution is indicated for the management of allograft rejection in renal transplant patients. When administered with conventional therapy at the time of rejection, it increases the frequency of resolution of the acute rejection episode. The drug has also been administered as an adjunct to other immunosuppressive therapy to delay the onset of the first rejection episode. Data accumulated to date have not consistently demonstrated improvement in functional graft survival associated with therapy to delay the onset of the first rejection episode.
ATGAM (lymphocyte immune globulin) is indicated for the treatment of moderate to severe aplastic anemia in patients who are unsuitable for bone marrow transplantation.
When administered with a regimen of supportive care, ATGAM (lymphocyte immune globulin) may induce partial or complete hematologic remission. In a controlled trial, patients receiving ATGAM (lymphocyte immune globulin) showed a statistically significantly higher improvement rate compared with standard supportive care at 3 months. Improvement was defined in terms of sustained increase in peripheral blood counts and reduced transfusion needs.
Clinical trials conducted at two centers evaluated the 1-year survival rate for patients with severe and moderate to severe aplastic anemia. Seventy-four of the 83 patients enrolled were evaluable based on response to treatment. The treatment groups studied consisted of 1) ATGAM (lymphocyte immune globulin) and supportive care, 2) ATGAM (lymphocyte immune globulin) administered following 3 months of supportive care alone, 3) ATGAM (lymphocyte immune globulin) , mismatched marrow infusion, androgens, and supportive care, or 4) ATGAM (lymphocyte immune globulin) , androgens, and supportive care. There were no statistically significant differences between the treatment groups. The 1-year survival rate for the pooled treatment groups was 69%. These survival results can be compared with a historical survival rate of about 25% for patients receiving standard supportive care alone.
The usefulness of ATGAM (lymphocyte immune globulin) has not been demonstrated in patients with aplastic anemia who are suitable candidates for bone marrow transplantation or in patients with aplastic anemia secondary to neoplastic disease, storage disease, myelofibrosis, Fanconi's syndrome, or in patients known to have been exposed to myelotoxic agents or radiation.
To date, safety and efficacy have not been established in circumstances other than renal transplantation and aplastic anemia.
Before the first infusion of ATGAM (lymphocyte immune globulin) , Pharmacia & Upjohn Company strongly recommends that patients be tested with an intradermal injection of 0.1 mL of a 1:1,000 dilution (5 µg horse IgG) of ATGAM (lymphocyte immune globulin) in sodium chloride injection, USP and a contralateral sodium chloride injection control. Use only freshly diluted ATGAM (lymphocyte immune globulin) for skin testing. The patient, and specifically the skin test, should be observed every 15 to 20 minutes over the first hour after intradermal injection. A local reaction of 10 mm or greater with a wheal or erythema, or both, with or without pseudopod formation and itching or a marked local swelling should be considered a positive test. Note: The predictive value of this test has not been proved clinically. Allergic reactions such as anaphylaxis have occurred in patients whose skin test is negative. In the presence of a locally positive skin test to ATGAM (lymphocyte immune globulin) , serious consideration to alternative forms of therapy should be given. The risk to benefit ratio must be carefully weighed. If therapy with ATGAM (lymphocyte immune globulin) is deemed appropriate following a locally positive skin test, treatment should be administered in a setting where intensive life support facilities are immediately available and with a physician familiar with the treatment of potentially life threatening allergic reactions in attendance.
A systemic reaction such as a generalized rash, tachycardia, dyspnea, hypotension, or anaphylaxis precludes any additional administration of ATGAM.
DOSAGE AND ADMINISTRATION
Renal Allograft Recipients
Adult renal allograft patients have received ATGAM (lymphocyte immune globulin) Sterile Solution at the dosage of 10 to 30 mg/kg of body weight daily. The few children studied received 5 to 25 mg/kg daily. ATGAM (lymphocyte immune globulin) has been used to delay the onset of the first rejection episode(2–5) and at the time of the first rejection episode.(6–10) Most patients who received ATGAM (lymphocyte immune globulin) for the treatment of acute rejection had not received it starting at the time of transplantation.
Usually, ATGAM (lymphocyte immune globulin) is used concomitantly with azathioprine and corticosteroids, which are commonly used to suppress the immune response. Exercise caution during repeat courses of ATGAM (lymphocyte immune globulin) ; carefully observe patients for signs of allergic reactions.
Delaying the Onset of Allograft Rejection: Give a fixed dose of 15 mg/kg daily for 14 days, then every other day for 14 days for a total of 21 doses in 28 days. Administer the first dose within 24 hours before or after the transplant.
Treatment of Rejection: The first dose of ATGAM (lymphocyte immune globulin) can be delayed until the diagnosis of the first rejection episode. The recommended dose is 10 to 15 mg/kg daily for 14 days. Additional alternate-day therapy up to a total of 21 doses can be given.
The recommended dosage regimen is 10 to 20 mg/kg daily for 8 to 14 days. Additional alternate-day therapy up to a total of 21 doses can be administered.(11–13) Because thrombocytopenia can be associated with the administration of ATGAM (lymphocyte immune globulin) , patients receiving it for the treatment of aplastic anemia may need prophylactic platelet transfusions to maintain platelets at clinically acceptable levels.
Preparation of Solution
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit. However, because ATGAM (lymphocyte immune globulin) is a gamma globulin product, it can be transparent to slightly opalescent, colorless to faintly pink or brown, and may develop a slight granular or flaky deposit during storage. ATGAM (lymphocyte immune globulin) (diluted or undiluted) should not be shaken because excessive foaming and/or denaturation of the protein may occur.
Dilute ATGAM (lymphocyte immune globulin) for intravenous infusion in an inverted bottle of sterile vehicle so the undiluted ATGAM (lymphocyte immune globulin) does not contact the air inside. Add the total daily dose of ATGAM (lymphocyte immune globulin) to the sterile vehicle (see Compatibility and Stability). The concentration should not exceed 4 mg of ATGAM (lymphocyte immune globulin) per mL. The diluted solution should be gently rotated or swirled to effect thorough mixing.
The diluted ATGAM (lymphocyte immune globulin) should be allowed to reach room temperature before infusion. ATGAM (lymphocyte immune globulin) is appropriately administered into a vascular shunt, arterial venous fistula, or a high-flow central vein through an in-line filter with a pore size of 0.2 to 1.0 micron. The in-line filter should be used with all infusions of ATGAM (lymphocyte immune globulin) to prevent the administration of any insoluble material that may develop in the product during storage. The use of high-flow veins will minimize the occurrence of phlebitis and thrombosis. Do not infuse a dose of ATGAM (lymphocyte immune globulin) in less than 4 hours. Always keep appropriate resuscitation equipment at the patient's bedside while ATGAM (lymphocyte immune globulin) is being administered. Observe the patient continuously for possible allergic reactions throughout the infusions (See ADVERSE REACTIONS).
Compatibility and Stability
ATGAM (lymphocyte immune globulin) , once diluted, has been shown to be physically and chemically stable for up to 24 hours at concentrations of up to 4 mg per mL in the following diluents: 0.9% sodium chloride injection, 5% dextrose and 0.225% sodium chloride injection, and 5% dextrose and 0.45% sodium chloride injection.
Adding ATGAM (lymphocyte immune globulin) to dextrose injection is not recommended, as low salt concentrations can cause precipitation. Highly acidic infusion solutions can also contribute to physical instability over time. It is recommended that diluted ATGAM (lymphocyte immune globulin) be stored in a refrigerator if it is prepared prior to the time of infusion. Even if it is stored in a refrigerator, the total time in dilution should not exceed 24 hours (including infusion time).
ATGAM (lymphocyte immune globulin) Sterile Solution, containing 50 mg of horse gamma globulin/mL, is supplied as follows:
5 – 5 mL ampoules.....................NDC 0009-7224-02
Store in a refrigerator at 2° to 8°C (36° to 46°F). DO NOT FREEZE.
2. Cosimi AB, Wortis HH, Delmonico FL, Russell PS: Randomized clinical trial of antithymocyte globulin in cadaver renal allograft recipients: importance of T cell monitoring. Surgery. 1976; 80:155–163.
3. Wechter WJ, Brodie JA, Morrell RM, Rafi M, Schultz JR: Antithymocyte globulin (ATGAM (lymphocyte immune globulin) ) in renal allograft recipients. Transplantation. 1979; 28(4):294–302.
4. Kountz SL, Butt KHM, Rao TKS, Zielinski CM, Rafi M, Schultz JR: Antithymocyte globulin (ATG) dosage and graft survival in renal transplantation. Transplant. Proc. 1977; 9:1023–1025.
5. Butt KMH, Zielinski CM, Parsa I, Elberg AJ, Wechter WJ, Kountz SL: Trends in immunosuppression for kidney transplantation. Kidney Int. 1978; 13(Suppl 8): S95–S98.
6. Filo RS, Smith EJ, Leapman SB: Reversal of acute renal allograft rejection with adjunctive ATG therapy. Transplant. Proc. 1981; 13(1): 482–490.
7. Nowygrod R, Appel G, Hardy M: Use of ATG for reversal of acute allograft rejection. Transplant. Proc. 1981; 13(1): 469–472.
8. Hardy MA, Nowygrod R, Elberg A, Appel G: Use of ATG in treatment of steroid-resistant rejection. Transplantation. 1980; 29:162–164.
9. Shield CH, Cosimi AB, Tolkoff-Rubin N, Rubin R, Herrin J, Russell PS: Use of antithymocyte globulin for reversal of acute allograft rejection. Transplantation. 1979; 28(6): 461–464.
10. Cosimi AB: The clinical value of antilymphocyte antibodies. Transplant. Proc. 1981; 13(1): 462–468.
11. Cosimi AB, Peters C, Harmon D, Ellman L: Treatment of severe aplastic anemia with a prolonged course of antithymocyte globulin. Transplant. Proc. 1982; 14:761–764.
12. Champlin R, Ho W, Gale R: Antithymocyte globulin treatment in patients with aplastic anemia. N Engl J Med. 1983; 308(3):113–118.
13. Doney K, Dahlberg S, Monroe D et al: Therapy of severe aplastic anemia with anti-human thymocyte globulin and androgens: The effect of HLA-haploidentical marrow infusion. Blood. 1984; 63(2):342–348.
Distributed by Pharmacia and Upjohn Company, Division of Pfizer Inc, NY, NY 10017. Revised November 2005. FDA Rev date: n/a
Last reviewed on RxList: 10/22/2008
This monograph has been modified to include the generic and brand name in many instances.
Additional Atgam Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get the latest treatment options.